Palonosetron

Palonosetron is a 5-HT3 antagonist primarily used to prevent acute, delayed, and overall chemotherapy-induced nausea and vomiting. Palonosetron exhibits moderate anti-flavivirus activity and potent anti-Zika virus activity in mammalian cells. Palonosetron also possesses antidepressant activity[1][2][3][4].

Product Specifications

CAS Number

[135729-61-2]

UNSPSC

12352005

Hazard Statement

H302

Target

5-HT Receptor; Flavivirus

Type

Reference compound

Related Pathways

Anti-infection; GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Infection; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/palonosetron.html

Solubility

10 mM in DMSO

Smiles

O=C1N(C[C@@]([H])(CCC2)C3=C2C=CC=C13)[C@@H]4CN5CCC4CC5

Molecular Formula

C19H24N2O

Molecular Weight

296.41

Precautions

P264-P270-P330-P501

References & Citations

[1]Barrows, et al. "A screen of FDA-approved drugs for inhibitors of Zika virus infection." Cell host & microbe 20.2 (2016) : 259-270. |[2]Rojas, et al. "Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor." Anesthesia & Analgesia 107.2 (2008) : 469-478. |[3]Wallenborn, et al. "Palonosetron hydrochloride in the prevention and treatment of postoperative nausea and vomiting." Clinical Medicine Insights: Therapeutics 2 (2010) : CMT-S4016.|[4]Sepúlveda-Vildósola, et al. "Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children." Archives of medical research 39.6 (2008) : 601-606. |[5]Sharma J, et al. Evaluation of antidepressant effect of palonosetron in Swiss albino mice[J]. National Journal of Pharmacology and Therapeutics, 2023, 1 (2) : 98-100.|[6]Rojas C, et al. The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther. 2010 Nov;335 (2) :362-8.